Clinical Trials | June 18, 2026
Suven reports positive Phase 2b results for Ropanicant in major depressive disorder
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Day-care model aimed at providing specialized psychological support for women during pregnancy and motherhood
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
